Adherent placenta is one of the important causes of post-partum hemorrhage. Placenta accreta-related pathologies are an increasing contributor to maternal death from hemorrhage. With the rising caesarean delivery rate the incidence of placenta accreta has significantly increased. Morbidly adherent placenta (MAP) occurs when there is a defect in the decidua basalis, resulting in an abnormal invasion of the placenta into the substance of the uterus. A multidisciplinary approach is relevant in managing these patients in order to reduce morbidity and mortality associated with morbidly adherent placenta. A non-surgical conservative method is to leave the placenta in situ to reabsorb and institute treatment with chemotherapeutic agents, such as methotrexate. With improvement in the medical services conservative management for adherent placenta has gained significance.
INTRODUCTION
Adherent placenta is one of the important causes of postpartum hemorrhage. Placenta accreta-related pathologies are an increasing contributor to maternal death from hemorrhage. 1 With the rising caesarean delivery rate the incidence of placenta accreta has significantly increased. 2 Morbidly adherent placenta (MAP) occurs when there is a defect in the decidua basalis, resulting in an abnormal invasion of the placenta into the substance of the uterus. 3 When this condition is not anticipated and attempts are made to deliver the placenta there can be catastrophic hemorrhage resulting in maternal mortality. Though the mortality due to placenta accreta has fallen from the early 20th century, the incidence of adherent placenta has increased from 0.025% in 1970s to 0.04% in 1990s. 4 Morbidly adherent placentation may be suspected when there is a placenta praevia in a woman with a history of caesarean section or other uterine surgery. 5 The term placenta accreta is used to describe any placental implantation that is adherent firmly to the uterine wall. Placental villi are anchored to the myometrium due to defective decidualization.
If villi invade the myometrium, the condition is called placenta increta. If the invasion goes as deep as reaching the serosal surface, this is called placenta percreta. If the placenta is thought to be low lying (less than 20 mm from the internal os) or praevia (covering the os) at the routine fetal anomaly scan, a follow-up ultrasound examination including a TVS is recommended at 32 weeks of gestation to diagnose persistent low-lying placenta and/or placenta praevia. 6 Placenta percreta is associated with a maternal mortality as high as 10% and significant maternal morbidity. 7 Uterine perforation and rupture into the urinary bladder are potential complications. 8 The reduction in mortality is mainly because of early diagnosis and changing trends in management especially expectant and medical methods with the availability of more sophisticated radiological investigations.
A 24-year-old female G2P1L1 with previous LSCS done 3yrs back with 24.6-week gestational age by her LMP came to obstetric casualty with c/o bleeding per vagina for 6 hours. The bleeding was painless and causeless. There were no h/o similar episodes of bleeding in the past. On examination, patient was pale but haemodynamically stable, size of uterus corresponded to 22-24 week, FHS not heard by Doppler and local examination showed minimal bleeding. She was started with intravenous tranexamic acid, injectable antibiotics and blood transfusion Ultrasound showed placenta praevia with placenta covering the internal os completely with multiple irregular lacunae of varying sizes seen within the placenta with accrete. There was no improvement in the patient with conservative management and there another active bout of bleeding. The decision for termination of pregnancy with conservation of uterus was made and possibility of obstetric hysterectomy explained to the patient and relatives.
Figure 1: Classical cesarean section done with vertical incision over the fundus and baby delivered.
Prophylactic b/l internal iliac artery ligation done followed by classical cesarean section. There was invasion of placenta through the serosa of the uterus reaching up to the bladder indicating placenta percreta. 24-week IUD baby was delivered, and placenta left in situ. Uterus closed in two layers. Hemostasis achieved. Patient was given 2-pint blood transfusion intra operatively and 3-pint blood transfusion and 4-pint FFP post operatively. Patient was given inj methotrexate at the dose of 1mg/kg on post op day 3. Patient had bleeding per vagina for 15 days and patient was discharged on post op day 17. Patient came with c/o pv bleeding on post op day 24 and passed mass per vagina which was found to be a placental cotyledon. Beta HCG level was done and was 117m IU/ml and was repeated one week later it was 82m IU/ml. Patient was followed up with serial beta HCG levels which showed a decreasing trend and serial USG with Doppler ( Figure 1 and 2). 
Case 2: A case of placenta increta
A 25-year-old female G5P3L3A1 with prev 3 LSCS with 31 weeks pregnancy came to obstetrics casualty with c/o bleeding per vagina. Ultrasound examination of the patient showed low lying placenta completely covering the internal os with loss of interface between the placenta and myometrium suggestive of global placenta accrete, scar thickness 6mm.
Figure 3: Classical cesarean section with vertical incision over the fundus of uterus taken.
On examination patient was haemodynamically stable, size of the uterus corresponded to 30wk of gestation, FHS present 136 beats/min, local examination showed minimal bleeding. Patient was admitted in the hospital and managed conservatively till 37-week of gestation. She had two similar episodes of bleeding pv during her stay in the hospital. 2-pint blood transfusion was given.
At 37-week of gestation patient was posted for classical caesarean section and consent for possible obstetric hysterectomy was taken. Classical caesarean section was done and a healthy male baby weighing 3.5 kg delivered. 
Case 3: A case of placenta accrete
A 25-year-old female G3P2L2 with prev 2 LSCS with 22-week pregnancy came to emergency room with c/o bleeding pv. Patient was haemodynamically stable and uterus corresponded to 22-week gestation with positive test for external ballotment. Ultrasound examination showed low lying placenta covering the internal os with adherent placenta at scar site s/o placenta accrete. Patient was managed conservatively and discharged against medical advice after 3 days. Patient came to obstetric casualty after one week with c/o excessive bleeding pv and in a state of shock. Her pulse was 126 beats per minute, BP 80/60mm of Hg with severe pallor. Two-pint blood transfused immediately and decision of emergency hysterotomy was done. Emergency laparotomy with b/l internal iliac artery ligation was done. Hysterotomy was done with transverse incision taken over lower part of upper uterine segment. A 22-week foetus was delivered and placenta left in situ. Uterus closed in layers. 2 Pint blood and 6-pint FFP transfusion done intra op and 6-pint blood transfusion given post op. Inj Methotrexate was delayed till blood counts were normal and given on post op day 6. Patient was discharged on day 12 without any complaints. She was followed up with serial ultrasound and beta HCG. Patient never had c/o excessive bleeding pv during the recovery period and recovered well. Placenta was completely autolysed in a span of 3 months.
DISCUSSION
A multidisciplinary approach is relevant in managing these patients in order to reduce morbidity and mortality associated with morbidly adherent placenta. Treatment for placenta percreta is primarily surgical, with hysterectomy being the treatment of choice in 93% of all cases. 9 Various modifications of the uterine incision to avoid the placenta have been reported. Classical incision, high transverse incision, fundal incision, fundal transverse incision has all been used. A non-surgical conservative method is to leave the placenta in situ to reabsorb and institute treatment with chemo-therapeutic agents, such as methotrexate. 10 Methotrexate, a folate antagonist, acts primarily against rapidly dividing cells, and therefore is effective against dividing trophoblast. In a case study conducted by Das et al, treatment of placenta accreta with methotrexate, Injection methotrexate was administered on the 16 th day following the regime of 1, 3, 5 and 7 with injection folinic acid on alternate days. 11 Methotrexate has been used in varying doses and routes, however, there are no randomized trials and no standard protocol regarding its dosage. 12 Washecka et al carried out a meta-analysis of 54 reported cases of placenta percreta. They noted that 31% of cases presented with haematuria. 13 In a case report of a case of placenta percreta by Mohan P et al had subtotal obstetric hysterectomy done for the case of placenta percreta and intraoperative blood loss was approximately 3.3 litres which was replaced with transfusion of 8 units of whole blood, 3 units of fresh frozen plasma and 2 units of platelet concentrates during the per-operative and postoperative period. 14 Morbid adhesion of placenta should be suspected even in women without any risk factors when there is postpartum hemorrhage and the same should be ruled by performing an immediate Ultrasonogram.
MRI is the best modality for confirmation of placenta accreta and increta. Medical management with methotrexate should be preferred over expectant management when there are no contraindications. This is essential to preserve the uterus for future fertility.
CONCLUSION
Abnormalities of placenta are one of the major factors affecting maternal and fetal outcome in obstetrics. Availability of excellent drugs like methotrexate aid in the conservative management facilitating autolysis of the placenta left in situ. With improvement in the medical services conservative management for adherent placenta has gained significance.
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